The Duchenne Muscular Dystrophy Treatment Market To Flaunt A CAGR Of 48.3% Between 2026 - PowerPoint PPT Presentation

About This Presentation
Title:

The Duchenne Muscular Dystrophy Treatment Market To Flaunt A CAGR Of 48.3% Between 2026

Description:

The global duchenne muscular dystrophy market is estimated to bring in US$ 10,664.5 million revenue by the end of 2026. – PowerPoint PPT presentation

Number of Views:22

less

Transcript and Presenter's Notes

Title: The Duchenne Muscular Dystrophy Treatment Market To Flaunt A CAGR Of 48.3% Between 2026


1
Duchenne Muscular Dystrophy Treatment Market
Report Id PMRREP12475 Category Life Science
Healthcare
2
About Persistence Market Research
Customized Research
Persistence Market Research(Persistence Market
Research) is a premier provider of syndicated
research reports, custom research reports, and
consulting services. We deliver a complete
packaged solution, which combines current market
intelligence, statistical anecdotes, technology
inputs, valuable growth insights, aerial view of
the competitive framework, and future market
trends. We provide research services at a global
as well as regional level key regions include
GCC, ASEAN, and BRIC. Our offerings cover a broad
spectrum of industries including Chemicals,
Materials, Energy, Technology, Healthcare, and
Retail. We have a global presence with delivery
centers across India specializing in providing
global research reports and country research
reports. Persistence Market Research is
headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Syndicated Research
Investment Research
Social Media Research
Research Capabilities
Sector Coverage
  • Customized Research
  • Syndicated Research
  • Investment Research
  • Social Media Research

  • Automotive and Transportation
  • Electronics, Semiconductor, and ICT
  • Retail and Consumer Products
  • Industrial Automation and Equipment
  • Chemicals Materials
  • Food and Beverages
  • Services and Utilities
  • Energy, Mining, Oil, and Gas


Subscription Information
For detailed subscription information please
contact Website www.persistencemarketresearch.co
m For sales queries or new topics email us on
sales_at_persistencemarketresearch.com
3
The Duchenne Muscular Dystrophy Treatment Market
To Flaunt A CAGR Of 48.3 Between 2026
  • As per the report by Persistence Market Research
    (PMR), the global duchenne muscular dystrophy
    market is expected to experience strong growth.
    The market is also estimated to expand at a CAGR
    of 48.3 during the forecast period. The global
    duchenne muscular dystrophy market is estimated
    to bring in US 10,664.5 million revenue by the
    end of 2026.
  • Duchenne Muscular Dystrophy (DMD) is a type of
    muscular disorder due to which most of the people
    are unable to walk at a very early stage and the
    affected muscles look larger due to the fat
    content. The symptoms include muscle weakness,
    difficulty in walking and breathing and
    intellectual disability.
  • Although, the treatment to control and reduce the
    signs and symptoms is available, yet there is no
    cure for DMD. Key players in the market are also
    trying to spread awareness about DMD along with
    the investment in finding a treatment for the
    disease. Meanwhile, human clinical trials are
    also underway to find out effective therapy.

Get Sample Copy of Report _at_ https//www.persistenc
emarketresearch.com/samples/12475
4
Increasing Investment in Research and Development
to find a Treatment for DMD to Drive the Market
Growth
Various pharmaceutical companies and
organizations are increasingly investing in the
research and development activities to come up
with an effective treatment for duchenne muscular
dystrophy. Meanwhile, there is an ongoing
research on gene therapy, exon skipping drugs,
and stem cell therapy to treat duchenne muscular
dystrophy in a better way. Current
pharmacological interventions for duchenne
muscular dystrophy include approaches to mitigate
downstream and secondary pathological mechanisms
and solutions targeting primary defect. Patients
with DMD are not able to produce a protein known
as dystrophin. Hence, a variety of new
medications are being developed to replace
dystrophin. Moreover, new therapies aim to
repair muscle damage caused due to the absence of
dystrophin. However, delay in diagnosis and the
high cost of treatment and drugs are some of the
factors restricting the growth of the market.
Access Full Report _at_ https//www.persistencemarket
research.com/checkout/12475
5
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com